Clara Pallares, MD
Internal Medicine · Louisville, KYNPI 1124092366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 25.3% of the total. Reporting peaked in 2021 at $3,156 and has fallen 64.8% since, to $1,111 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$464
- Boehringer Ingelheim$461
- plus $4K from 28 others
What the payments were for
- Food & beverage$13,186100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $3,344 |
| Novo Nordisk | 104 | $2,050 |
| AbbVie(2 entities) | 98 | $1,687 |
| GSK | 33 | $1,679 |
| Regeneron Healthcare Solutions, Inc. | 4 | $464 |
| Boehringer Ingelheim | 11 | $461 |
| Lilly USA, LLC | 23 | $427 |
| Amgen(2 entities) | 16 | $422 |
| Merck | 12 | $294 |
| Pfizer | 5 | $263 |
| Incyte Corporation | 2 | $242 |
| Sanofi | 2 | $227 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $191 |
| Exact Sciences | 10 | $182 |
| Biohaven Pharmaceuticals, Inc. | 2 | $135 |
| Edwards Lifesciences | 1 | $131 |
| Galderma Laboratories, L.p. | 1 | $130 |
| Bayer | 8 | $126 |
| Shire North American Group Inc | 1 | $116 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $75 |
| Sanofi Pasteur Inc. | 4 | $61 |
| Abbott | 3 | $50 |
| Philips North America LLC | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Medtronic | 1 | $25 |
| Flowonix Medical Incorporated | 1 | $24 |
| Mckesson Medical-surgical, Inc. | 1 | $20 |
| Qiagen, LLC | 1 | $19 |
| Alvogen Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,192 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $159,593 |
| FarxigaDapagliflozin Propanediol | 94 | $85,043 |
| JardianceEmpagliflozin | 65 | $78,039 |
| EliquisApixaban | 57 | $62,123 |
| RybelsusSemaglutide | 30 | $57,032 |
| TrulicityDulaglutide | 27 | $38,612 |
| Repatha SureclickEvolocumab | 24 | $33,584 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $33,521 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,840 |
| JanuviaSitagliptin Phosphate | 16 | $21,531 |
| MounjaroTirzepatide | 20 | $20,871 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $19,843 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $18,422 |
| XareltoRivaroxaban | 19 | $16,415 |
| MyrbetriqMirabegron | 13 | $15,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,050 | $216,625126 claims |
| AstraZenecaFarxiga, Symbicort | $3,344 | $90,589110 claims |
| Boehringer IngelheimJardiance | $461 | $78,03965 claims |
| PfizerEliquis | $263 | $62,12357 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $427 | $59,48347 claims |
| MerckJanuvia, Janumet Xr | $294 | $41,37428 claims |
| GSKTrelegy Ellipta | $1,679 | $31,84039 claims |
| AbbVieSynthroid | $1,687 | $3,00077 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Lal TanwaniLouisville$38K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Frank SimonLouisville$22K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
- Yiyi TsaiLouisville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.